Sign in Register

Drug class

Incretin Mimetic/GLP-1 and Dual GIP/GLP-1 Receptor Agonist

The phrase "Incretin Mimetic/GLP-1 and Dual GIP/GLP-1 Receptor Agonist" is a compound compendial classification phrase—represented clinically by tirzepatide—combining traditional incretin mimetics with dual incretin receptor agonists. Read more about Incretin Mimetic/GLP-1 and Dual GIP/GLP-1 Receptor Agonist

30 drugs in this class 11 manufacturers

Advertisement

Related classes & indications

Antihyperglycemic-dipeptidyl peptidase-4 (DPP-4) InhibitorsEndocrine & metabolic · 49 prescription drugs 5 Alpha-Reductase InhibitorsEndocrine & metabolic · 44 prescription drugs Type 2 Diabetes MellitusTop indication · 579 prescription drugs

Drugs in Incretin Mimetic/GLP-1 and Dual GIP/GLP-1 Receptor Agonist

Showing 10–18 of 30 drugs

OZEMPIC (semaglutide)

INCRETIN MIMETIC/GLP-1 AND DUAL GIP/GLP-1 RECEPTOR AGONIST · TYPE 2 DIABETES MELLITUS ·+2
NOVO NORDISK

RYBELSUS (semaglutide)

INCRETIN MIMETIC/GLP-1 AND DUAL GIP/GLP-1 RECEPTOR AGONIST · TYPE 2 DIABETES MELLITUS ·+1
NOVO NORDISK

WEGOVY (semaglutide)

DIET AIDS · WEIGHT LOSS MANAGEMENT FOR OBESE PATIENT (BODY MASS INDEX 30 OR GREATER) ·+3
NOVO NORDISK

MOUNJARO (tirzepatide)

INCRETIN MIMETIC/GLP-1 AND DUAL GIP/GLP-1 RECEPTOR AGONIST · TYPE 2 DIABETES MELLITUS ·+1
Eli Lilly and Company

LIRAGLUTIDE

DIET AIDS · TYPE 2 DIABETES MELLITUS
TEVA PHARM

LIRAGLUTIDE

INCRETIN MIMETIC/GLP-1 AND DUAL GIP/GLP-1 RECEPTOR AGONIST · TYPE 2 DIABETES MELLITUS
A-S MEDICATION
Filter & compare in the drug finder → Opens the drug finder with Incretin Mimetic/GLP-1 and Dual GIP/GLP-1 Receptor Agonist preselected. Add indication or manufacturer filters there.

About Incretin Mimetic/GLP-1 and Dual GIP/GLP-1 Receptor Agonist.

The phrase "Incretin Mimetic/GLP-1 and Dual GIP/GLP-1 Receptor Agonist" is a compound compendial classification phrase—represented clinically by tirzepatide—combining traditional incretin mimetics with dual incretin receptor agonists.

Agents in this category activate both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors to enhance glucose-dependent insulin release, reduce glucagon secretion, slow gastric emptying, and suppress central appetite signaling.

Clinically, these agents are primarily indicated for improving glycemic control in adults with type 2 diabetes mellitus and for chronic weight management in patients with obesity or overweight accompanied by weight-related comorbidities.